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SUMMARY Background
Vedolizumab is a gut-selective immunoglobulin G 1 monoclonal antibody to a 4 b 7 integrin for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Prospective clinical studies of vedolizumab in pregnancy have not been conducted; therefore, existing safety data of vedolizumab in pregnancy were examined.
Aim
To assess pregnancy outcomes in females and partners of males who received vedolizumab.
INTRODUCTION
Vedolizumab is a humanised immunoglobulin G 1 (IgG 1 ) monoclonal antibody (mAb) approved for use in adults with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC), based on clinical trials with exposure follow-up of up to 5 years. [1] [2] [3] Vedolizumab binds to a 4 b 7 integrin, selectively modulating gut lymphocyte trafficking and avoiding the undesirable systemic effects associated with non-a 4 b 7 -selective integrin inhibition. 4 Because inflammatory bowel disease (IBD) affects women during their reproductive years, safety of IBD medications during pregnancy is of great concern to patients and physicians. Active IBD prior to conception and during pregnancy has been shown to correlate with poorer pregnancy outcomes, 5, 6 underscoring the need for continued medical management of this condition during pregnancy. A reproductive study of vedolizumab in pregnant primates has demonstrated no evidence of any adverse effects on pre-or post-natal development after intravenous administration of vedolizumab at dose levels 20 times the equivalent of those recommended for humans. 7 To date, no clinical studies investigating the effect of vedolizumab in pregnancy have been performed. However, an Organization of Teratology Information Services (OTIS) observational pregnancy registry, enrolling pregnant patients with UC or CD on vedolizumab, is currently on-going (NCT02678052). 8 In addition, all real-world data on vedolizumab-associated pregnancies [whether associated with an adverse event (AE) or not] reported to vedolizumab manufacturer Takeda are monitored in a vedolizumab global safety database. IgG antibody transfer is known to increase from about week 16 of gestation, 9 and several studies have demonstrated the placental transfer of anti-TNF biologic agents in IBD. [10] [11] [12] Placental transfer of vedolizumab is expected to be similar to that shown for other therapeutic IgG 1 antibodies 13 and vedolizumab should be used during pregnancy only if the benefits to the mother outweigh the potential risks to the mother and unborn child. 7, 14, 15 Against this background, we conducted an analysis to document and evaluate the pregnancy outcomes of female study participants and partners of male participants (indirect exposure) treated with vedolizumab in the vedolizumab clinical development programme.
MATERIALS AND METHODS
Vedolizumab exposure during clinical studies Female participants were screened for pregnancy throughout six clinical studies involving vedolizumab (Table S1) .
At study entry, females who were pregnant or lactating were excluded, and females at risk of pregnancy were required to be taking contraceptive measures. Women were required to inform the investigator immediately and to permanently discontinue the study drug if they became pregnant or suspected they were pregnant while participating in a study (or within 6 months of the last dose of study drug for three of the protocols). Pregnant females were monitored to determine the final pregnancy outcome.
Male participants in the same six clinical studies were able to remain in the study and continue receiving treatment but were required to report if their partner became pregnant during participation (or within 6 months of the last dose of study drug for three of the protocols). Every effort was made to follow the pregnancy to determine the final outcome.
Data on all pregnancies collected from 14 May 2007 until 27 June 2013 were collated and analysed.
Post-marketing safety data All pregnancies temporally associated with vedolizumab treatment that are reported to Takeda are held in a vedolizumab global safety database (whether associated with an AE or not). Sources of pregnancy data included spontaneous reports received directly from patients, healthcare professionals or regulatory authorities; reports in the scientific and medical literature; and solicited reports from patient support programmes and market research programmes.
Upon receipt of a pregnancy report, Takeda reviewed the data and, if not provided, requested details of the woman's medical history, previous pregnancies, medications used during the pregnancy and pregnancy outcome, as well as birth and delivery information and information on the infant. If the pregnancy was reported with an AE, the AE was followed up in accordance with routine pharmacovigilance procedures.
The vedolizumab global safety database was searched for pregnancy reports entered up to 19 November 2015 using the following Medical Dictionary for Regulatory Activities (MedDRA) version 18.1 16 search criteria:
(i) An event Preferred Term (PT) in the 'Normal pregnancy conditions and outcomes' Standard MedDRA Queries (SMQ) (Narrow) or
(ii) An event PT in the 'Pregnancy, labour and delivery complications and risk factors (excluding abortions and stillbirth)' SMQ (Narrow) or (iii) An event PT in the 'Termination of pregnancy and risk of abortion' SMQ (Narrow)
To ensure that all pregnancy reports were identified, the following search criteria were applied to fields in the global safety database:
(i) Pregnant field on the Case Patient tab was 'Yes' (ii) Case Classification was 'Pregnancy' (iii) Case Classification was 'No AE -Pregnancy'
RESULTS
Pregnancies during clinical studies of vedolizumab A total of 46 pregnancies were reported from six vedolizumab clinical trials, which included 27 female study participants (25 patients with CD or UC and two healthy volunteers) and 19 pregnancies in partners of male participants (Table S1 ). Of the 27 female participants who became pregnant, 24 received vedolizumab and three received placebo (Table 1) . Of the 19 pregnancies that occurred in partners of male participants, 15 occurred in partners of participants exposed to vedolizumab (Table 1) . Outcomes for all pregnancies were documented at the time of reporting, with the exception of those for four female participants and three partners of male participants, all of whom were in the vedolizumab treatment group.
Pregnancies in vedolizumab-treated study participants (direct exposure) Live births. Eleven of the 24 vedolizumab-treated participants had live births, nine at full term ( Table 2) . IBD disease activity for the 11 mothers, recorded within 3 months of the last menstrual period (LMP), ranged from moderate disease to remission. There were two premature births (<37 weeks' gestation) reported, one to a mother with a history of pre-term pregnancies; the obstetric history of the other mother was not available. Moderate IBD disease activity was reported within 3 months of the LMP for both mothers.
A congenital anomaly was reported in one live birth by a 28-year-old healthy female volunteer who had received a single dose of vedolizumab (2 mg/kg) during study C13001. The infant was born 'at term' and diagnosed at 1.5 months of age with a Grade 4 congenital central nervous system anomaly caused by agenesis of the corpus callosum and left frontal polymicrogyria. In accordance with the C13001 protocol, blood samples for pharmacodynamic and pharmacokinetic assessment were obtained from the participant at regular intervals during a 150-day observation period after the single dose of vedolizumab. At the estimated time of conception (79 days after the vedolizumab infusion), serum vedolizumab concentrations were low although saturation of a 4 b 7 integrin was still near-complete ( Figure 1 ). At the estimated time of the corpus callosum organogenesis (149 days after vedolizumab infusion), vedolizumab had been largely eliminated, with desaturation of vedolizumab-binding sites on a 4 b 7 integrin. Of note, this volunteer had an extensive obstetric history including two therapeutic abortions, one ectopic pregnancy, two miscarriages and a caesarean delivery (Table 2) .
Spontaneous abortions. Four vedolizumab-treated participants had spontaneous abortions (Table 3) , three of which occurred within the first trimester. According to available obstetric history, three of the four participants each reported one previous live birth. Moderate-to-severe CD, Crohn's disease; UC, ulcerative colitis.
*Number of pregnancies in female study participants/number of pregnancies in partners of male study participants. †Includes the congenital anomaly outcome. ‡Includes pregnancies that were on-going at last participant contact.
and severe IBD disease activity was reported for the two patients for whom disease activity scores were available at the time of spontaneous abortion.
Elective terminations. Five vedolizumab-treated participants had elective terminations, one of which was reported as therapeutic although no specific reason was given.
Pregnancies in placebo-treated study participants One live birth and two spontaneous abortions were reported for placebo-treated participants. One spontaneous abortion occurred in an 18-year-old patient with CD 112 days after receiving a single dose of placebo. The investigator considered the spontaneous abortion to be probably related to a dose of methotrexate, an abortifacient, 17 which had been administered 2 weeks prior to conception. No further information was reported for the other pregnancies in placebo-treated study participants.
Pregnancies in partners of male vedolizumab-treated study participants (indirect exposure) Of the 15 pregnancies that occurred in partners of male participants exposed to vedolizumab, eight live births were reported; two of these were premature. Two spontaneous abortions occurred in individuals with a history of pre-term pregnancies. One event occurred due to a blighted ovum after 8 weeks of gestation and the other due to single nuchal cord resulting in foetal death in the third trimester. The study investigator considered both spontaneous abortions to be unrelated to the study drug.
Two elective terminations were reported, one of which occurred in a 36-year-old female and was classified as therapeutic due to a defect of unknown attribution detected in chorionic villi.
No outcomes were reported for the remaining three pregnancies that occurred in partners of male participants exposed to vedolizumab.
Post-marketing safety data
Up to 19 November 2015, 81 pregnancies were reported globally in the post-marketing setting. These were from 79 female patients treated with vedolizumab and two partners of male patients treated with vedolizumab. In total, 24 (29.6%) of the 81 pregnancies were associated with one or more AE. Pregnancy outcome data exist for 15 of these AE-associated pregnancies; in nine of these, the only AE reported was the pregnancy outcome (i.e. spontaneous/missed abortion). No pregnancy outcome data were available for either the remaining nine AEassociated pregnancies or for any non-AE-associated pregnancies. Disease activity data were not available for any of the patients in this post-marketing analysis.
In the 15 pregnancies for which a pregnancy outcome was recorded, there were four live births (Table S2) . Two births were premature without any associated complications; one infant was delivered 10 days prior to the expected due date by Caesarean section because of a low heart rate. This infant had a low birth weight as a result of an umbilical cord abnormality and decreased nutrition. The fourth infant, born prematurely to a 28-yearold patient with CD, died postpartum. This patient had begun vedolizumab treatment 6 weeks after pregnancy was confirmed and had a normal course of pregnancy up to gestational week 24. Ultrasonography at gestational week 26 showed foetal growth restriction and decreased amniotic fluid volume. The patient was hospitalised and labour was induced at that point. No autopsy of the child was performed, but histology of the placenta showed placental insufficiency. This was the patient's first pregnancy; her medical history included colostomy and anal fistula. Concomitant medications are detailed in Table S2 .
In all, 10 spontaneous abortions and one missed abortion were reported. Where data were available, all spontaneous and missed abortions occurred within the first trimester (Table S3 ). The pregnancy outcome for 66 (81.5%) pregnancies was either not stated, or the pregnancy was on-going at the time of the report.
DISCUSSION
It is recommended that IBD remission should be achieved prior to conception. [18] [19] [20] Quiescent disease is believed to have minimal impact on the course and outcome of pregnancy, whereas patients with active disease at conception have increased rates of spontaneous abortion, pre-term birth, low birth weight and infants that are small for gestational age. 18, [21] [22] [23] Interpretation of the impact of IBD disease activity on pregnancy outcome in vedolizumab-treated females is confounded by incomplete availability of data and the small numbers of patients; however, generally more severe disease activity was recorded in individuals experiencing a pre-term live birth or spontaneous abortion than in those with a fullterm pregnancy. To control disease optimally and maintain remission, many patients require therapy throughout pregnancy. 19, 20, 22, 24 Consequently, it is vital to consider the effect of IBD medications on foetal health. Generally, the greatest risk to mother and foetus during pregnancy is active IBD, not the medication used to treat it. 15 Indeed, exposure to most IBD medications is considered to be low risk to the foetus; this excludes methotrexate and thalidomide, 18, 25 both of which are administered 'off-label' for the treatment of IBD. 26, 27 Current guidelines for the management of IBD in pregnancy recommend stable remission off steroids on needed maintenance medications such as 5-aminosalicylic acid, thiopurines and/or biologic agents. 18, 25 Recommendations on the use of a 4 b 7 integrin inhibitors in pregnancy are not yet included in the recently published general clinical consensus statements because of the lack of published data. 15, 18, 25 In our analysis of six vedolizumab studies, there were 24 pregnancies in vedolizumab-treated females. There was one congenital anomaly reported -agenesis of the corpus callosum in the baby of a healthy volunteer exposed to a single dose of vedolizumab. Given the mother's extensive obstetric history and the virtual elimination of vedolizumab at the estimated time of the corpus callosum organogenesis, maternal factors other than vedolizumab exposure may potentially provide an explanation for this congenital anomaly. Although the sample size in this analysis is small, the available data do not associate vedolizumab exposure during pregnancy with any new safety concerns.
The data from 15 vedolizumab-exposed partner pregnancies are difficult to interpret because of the small study numbers and limited and variable consistency of data reported although there was no evidence of a signal for an adverse effect of vedolizumab exposure on pregnancy outcome.
Comparison of pregnancy outcomes among vedolizumabtreated patients with placebo recipients is not appropriate given the small numbers involved.
Determination of the safety profile of a drug in utero is complicated both by ethical concerns and the obvious difficulty in recruiting willing participants to clinical studies in this regard. It is therefore necessary to find acceptable and effective alternatives to address this issue. The most obvious way this can be achieved is by re-examining available existing clinical data on the drug in question, as has been undertaken in this report for vedolizumab. A second important way in which in utero safety concerns can be further studied is through postmarketing pharmacovigilance data on the use of the drug during pregnancy. Takeda has received postmarketing safety reports of vedolizumab use during pregnancy from various sources. These include a total of 81 pregnancies in 79 female patients treated with vedolizumab and two pregnancies in partners of two male patients treated with vedolizumab. Of the 81 pregnancies, only 15 (18.5%) reports included pregnancy outcomes -all of which also included reporting of an AE. An additional nine AE-associated pregnancies were reported, but no pregnancy outcome data were available (Tables S2 and S3 ). There were four live births (Table S2 ) and 11 spontaneous and missed abortions (Table S3) , all during the first trimester. Of note, no congenital anomalies were reported. Unfortunately, the level of detail contained in spontaneous post-marketing reports is variable and, despite diligent follow-up in these pregnancy reports, the information forthcoming was limited. The nature of spontaneous reporting in the post-marketing setting is such that pregnancies associated with AEs are more likely to be reported than those with normal pregnancies and positive outcomes for mother and child. Therefore, given the incomplete information reported and the known tendency of reporting negative outcomes, meaningful interpretation is constrained as pregnancies with positive outcomes are likely to have been under reported.
The analyses of the clinical development programme experience are consistent with the supposition that vedolizumab is likely to display a safety profile similar to other IgG 1 therapeutic antibodies, such as infliximab 28 and adalimumab, with respect to pregnancy. 29, 30 Although infants are born with higher levels of drug than the mother when the IgG 1 anti-TNF therapies infliximab and adalimumab are administered throughout pregnancy, 12 there is no evidence that these agents are associated with adverse pregnancy or newborn outcomes (such as congenital abnormalities, pre-term birth or low birth weight) compared with disease-matched controls or the general population. 31, 32 Furthermore, for the 96 (of 131 total) pregnancies identified in the infliximab safety database as having direct exposure to the agent, rates of live births, miscarriages and therapeutic terminations (67%, 15% and 19%, respectively) were similar to those expected both in a healthy population (67%, 17% and 16%, respectively) and in a population of patients with CD who were not exposed to infliximab (66%, 17% and 11%, respectively). 33 The equivalent rates for the 20 pregnancies with known outcomes in the vedolizumab clinical development programme (55%, 20% and 25%, respectively) are not too dissimilar from these when allowance for the much smaller population size is made. In the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes (PIANO) registry, which documented pregnancy outcomes for 797 patients with IBD [including 102 exposed to anti-TNF biologics (infliximab, adalimumab and certolizumab) and 59 exposed to both thiopurines and anti-TNF agents], thiopurines and anti-TNF therapies were not associated with an increase in spontaneous abortion, congenital anomalies, pre-term birth, intrauterine growth retardation, Caesarean section or neonatal intensive care unit stays, even when adjusted for disease type or activity. However, an increase in commonly observed infections in infants aged 9-12 months who were exposed to a combination of immunomodulators and biologics during pregnancy was reported. 34 IgG antibodies are the only class of antibody that significantly cross the human placenta and provide shortterm passive immunity to the newborn. 13 Active transfer of IgG antibodies from mother to foetus begins in the second trimester and the rate increases as pregnancy progresses, with the majority of transfer occurring during the third trimester. 35 As a result, it has been demonstrated that there are significantly lower levels of seroprotection to vaccine-preventable diseases, such as measles, mumps and rubella, in pre-term compared with full-term infants. 36 At term, foetal IgG levels typically exceed those of the mother. In the context of biologic IBD therapies, this may protect the infant from exposure during the crucial period of organogenesis in the first trimester; however, the high rate of placental transfer in the third trimester means that the IBD biologic can be present in the infant for several months after birth. The data from clinical studies and the post-marketing data from the global safety database do not indicate any safety concerns related to pregnancy outcomes in pregnant females directly or indirectly exposed to vedolizumab. An observational pregnancy (OTIS) registry, enrolling pregnant patients with UC or CD receiving vedolizumab, is currently on-going (NCT02678052). 8 This study will provide further insight into the prevalence of major structural birth defects in infants of female participants with UC or CD exposed to vedolizumab during pregnancy, compared with participants with UC or CD exposed to other biologic agents. Current prescribing information for vedolizumab states that this drug should be used during pregnancy only if the benefits to the mother outweigh the risks to the mother and unborn child. 7, 14, 15 The current general clinical consensus for the treatment of pregnant women with IBD includes continuation of anti-TNF therapy throughout pregnancy, with the consideration to modify the dosing schedule during the third trimester. 25 However, there are differences between regions, with the European consensus including a consideration to discontinue anti-TNF agents around gestational weeks 24-26 to limit placental transport to the foetus in the third trimester. 18 The gestational weeks 24-26 half-lives of infliximab and adalimumab are 7.7-9.5 and 10-20 days, respectively, 28, 29 whereas the half-life of vedolizumab in nonpregnant individuals is longer, at 25.5 days. 39 Consequently, assuming dosing according to the label, withholding vedolizumab administration during the third trimester would still result in substantial concentrations being present in the mother's system as the third trimester begins, and would theoretically result in substantial concentrations in the foetus prior to delivery. 40 The reduced postpartum clearance rate of IgG from newborns is also an important consideration because this would imply an increased exposure of the foetus. 12 Although the intentional use of vedolizumab during pregnancy requires appropriate deliberation on a case-by-case basis, there was no clear adverse pregnancy outcome in the data described from the clinical study 30 or post-marketing data from the global safety database.
Limitations of this analysis include the small number of pregnancies recorded during the vedolizumab clinical development programme and the requirement that female study participants who became pregnant stop taking vedolizumab. Although these key aspects limit the ability to draw firm conclusions, further documentation from the on-going vedolizumab clinical trial programme, post-marketing spontaneous reporting and the on-going pregnancy registries will increase our understanding in this area.
In summary, available data from pregnant females either directly or indirectly exposed to vedolizumab do not indicate safety concerns related to pregnancy outcomes for this intravenously administered IgG 1 mAb. The on-going registry will provide further insight into the benefit-risk profile of vedolizumab during pregnancy. In the meantime, the current prescribing information indicates that this agent should be used during pregnancy only if the benefits to the mother outweigh the risks to the mother and unborn child.
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